About: Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis
Creator	Li, Wei Wu, Jun Wang, Lei Li, Ying Hao, Jie Dai, Huaping Huo, Yan Liu, Peipei Gao, Tingting Peng, Liang Zhou, Qi Jin, Ronghua Stacey, Glyn Wang, Zai Wang, Liu Chen, Yanxia Feng, Chunjing Feng, Guihai Guo, Baojie Hu, Baoyang Hu, Zheng Li, Zhongwen Liang, Lingmin Liu, Wenjing Shyh-Chang, Ng Song, Dingyun Wang, Yukai Wen, Jianyan Xiao, Yani Yang, Shengnan
topic	covid:ec775fad13a65756a393f677c7bcb5d1ee4eba1b#this
Source	Medline; PMC
abstract	Lung injury and fibrosis represent the most significant outcomes of severe and acute lung disorders, including COVID-19. However, there are still no effective drugs to treat lung injury and fibrosis. In this study, we report the generation of clinical-grade human embryonic stem cells (hESCs)-derived immunity- and matrix-regulatory cells (IMRCs) produced under good manufacturing practice requirements, that can treat lung injury and fibrosis in vivo. We generate IMRCs by sequentially differentiating hESCs with serum-free reagents. IMRCs possess a unique gene expression profile distinct from that of umbilical cord mesenchymal stem cells (UCMSCs), such as higher expression levels of proliferative, immunomodulatory and anti-fibrotic genes. Moreover, intravenous delivery of IMRCs inhibits both pulmonary inflammation and fibrosis in mouse models of lung injury, and significantly improves the survival rate of the recipient mice in a dose-dependent manner, likely through paracrine regulatory mechanisms. IMRCs are superior to both primary UCMSCs and the FDA-approved drug pirfenidone, with an excellent efficacy and safety profile in mice and monkeys. In light of public health crises involving pneumonia, acute lung injury and acute respiratory distress syndrome, our findings suggest that IMRCs are ready for clinical trials on lung disorders.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1038/s41422-020-0354-1
bibo:pmid	32546764
has license	cc-by
sha1sum (hex)	ec775fad13a65756a393f677c7bcb5d1ee4eba1b
schema:url	https://doi.org/10.1038/s41422-020-0354-1
resource representing a document's title	Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis
has PubMed Central identifier	PMC7296193
has PubMed identifier	32546764
schema:publication	Cell Res
resource representing a document's body	covid:ec775fad13a65756a393f677c7bcb5d1ee4eba1b#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/ec775fad13a65756a393f677c7bcb5d1ee4eba1b
is schema:about of	named entity 'generate' named entity 'lung' named entity 'unique' named entity 'human embryonic stem cells' named entity 'ARTICLE' named entity 'GENE EXPRESSION PROFILE' named entity 'MECHANISMS' named entity 'REGULATORY' named entity 'FIBROTIC' named entity 'REPORT' named entity 'LUNG INJURY' named entity 'GENERATION' named entity 'ACUTE LUNG INJURY' named entity 'UMBILICAL CORD' named entity 'DOSE-DEPENDENT' named entity 'GOOD MANUFACTURING PRACTICE' covid:arg/ec775fad13a65756a393f677c7bcb5d1ee4eba1b named entity 'human embryonic stem cells' named entity 'primary' named entity 'vivo' named entity 'drug' named entity 'fibrosis' named entity 'pneumonia' named entity 'However' named entity 'pirfenidone' named entity 'fibrosis' named entity 'safety' named entity 'injury' named entity 'lung injury' named entity 'cells' named entity 'derived' named entity 'acute respiratory distress syndrome' named entity 'gene expression profile' named entity 'fibrosis' named entity 'intravenous' named entity 'lung injury' named entity 'Lung injury' named entity 'clinical trials' named entity 'human embryonic stem cells' named entity 'teratomas' named entity 'anti-fibrotic' named entity 'expressed genes' named entity 'protein expression' named entity 'collagen' named entity 'fluorescence' named entity 'GREM1' named entity 'pro-inflammatory cytokines' named entity 'Somatic Cell' named entity 'Illumina' named entity 'serum samples'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software